Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal

Table 2 Distribution of metabolic components in study population

Metabolic components	Control	NAFLD	X²	OR (95%CI)
Age: > 50 years	10%	16.4%	1.28	0.56(0.21–1.53)
BMI: ≥25 kg/m²	30%	57.5%	10.99	3.16(1.58–6.31)^a
WC: > 94 cm (M),> 80 cm (F)	11.4%	56.1%	31.75	0.10(0.04–0.24)^a
WC: > 102 cm (M),88 cm (F)	1.4%	30.1%	21.821	29.76(3.88–228.03)^a
Blood Pressure: ≥130/85 mmHg	35.7%	56.1%	6.01	2.30(1.17–4.50)
TG: ≥150 mg/dl	2.9%	60.27%	53.98	51.58(11.71–227.12)^a
Low HDL: < 40 mg/dl(M),< 50 mg/dl (F)	47.1%	69.8%	7.61	2.59(1.30–5.16)^b
MetS + (NCEP ATPIII-criteria)	1.4%	13.6%	10.31	2.15(1.70–2.52)^b
MetS + (IDF-criteria)	1.4%	30.1%	21.82	29.75(3.888–228.03)^a

^a-p < 0.001, ^b-p < 0.005
F female, M male, MetS + (NCEPATPIII) metabolic syndrome present by National Cholesterol Education Program Adult Treatment Panel III, MetS + (IDF) metabolic syndrome present by International Diabetic Federation

ISSN: 1471-230X